Awakn Establishes Separate Preclinical and Clinical Expert Advisory Boards to Optimize Delivery of Its Expanding Development Pipeline
Awakn's Chief Research Officer Prof. David Nutt Will Chair Both Advisory Boards with Prof. Stephen Husbands, Prof. Harriet De Wit, and Prof. Kevin Fone Joining the Preclinical Advisory Board
- Toronto, Ontario--(Newsfile Corp. - July 7, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, announced today that it will establish separate preclinical and clinical expert advisory boards to add to its existing Scientific Advisory Board's capabilities, to optimize delivery of its expanding development pipeline.
- Awakns new clinical and preclinical boards will ensure that Awakn adopts and delivers optimum strategies to bring new therapeutic paradigms to market rapidly.
- These pioneering boards consist of leading preclinical and clinical experts in the fields of drug discovery, psychedelic drug development and clinical trials.
- Awakn is delighted to announce the addition of Prof. Stephen Husbands, Prof. Harriet de Wit, and Prof. Kevin Fone to the Preclinical Advisory board.